LT2960253T - Žmogaus monokloniniai antikūnai prieš aktivino receptoriaus tipo kinazę-1 - Google Patents

Žmogaus monokloniniai antikūnai prieš aktivino receptoriaus tipo kinazę-1

Info

Publication number: LT2960253T
Authority: LT; Lithuania
Prior art keywords: kinase; monoclonal antibodies; human monoclonal; activin receptor; activin
Prior art date: 2005-09-07

Application number

LTEP15169743.0T

Other languages

English (en)

Inventor

Michael Aidan North

Jianying Wang

Grant Raymond Wickman

Jingchuan Zhang

Karin Kristina Amundson

Vahe Bedian

Shelley Sims Belouski

Dana Dan Hu-Lowe

Xin Jiang

Shannon Marie Karlicek

Sirid-Aimee Kellermann

James Arthur Thomson

Original Assignee

Amgen Fremont Inc.

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-07

Filing date

2006-09-06

Publication date

2018-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2960253(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-09-06 Application filed by Amgen Fremont Inc., Pfizer Inc. filed Critical Amgen Fremont Inc.

2018-10-10 Publication of LT2960253T publication Critical patent/LT2960253T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Wood Science & Technology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Physics & Mathematics (AREA)
Endocrinology (AREA)

LTEP15169743.0T 2005-09-07 2006-09-06 Žmogaus monokloniniai antikūnai prieš aktivino receptoriaus tipo kinazę-1 LT2960253T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71529205P	2005-09-07	2005-09-07

Publications (1)

Publication Number	Publication Date
LT2960253T true LT2960253T (lt)	2018-10-10

Family

ID=37906640

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15169743.0T LT2960253T (lt)	2005-09-07	2006-09-06	Žmogaus monokloniniai antikūnai prieš aktivino receptoriaus tipo kinazę-1

Country Status (40)

Country	Link
US (3)	US7537762B2 (lt)
EP (4)	EP1933871B1 (lt)
JP (3)	JP5161777B2 (lt)
KR (3)	KR101536506B1 (lt)
CN (2)	CN101517068B (lt)
AP (2)	AP2723A (lt)
AR (2)	AR055152A1 (lt)
AU (1)	AU2006297571B2 (lt)
BR (1)	BRPI0615766A2 (lt)
CA (1)	CA2621371C (lt)
CL (1)	CL2010000096A1 (lt)
CR (3)	CR9819A (lt)
CY (1)	CY1120794T1 (lt)
DK (3)	DK2447283T3 (lt)
DO (1)	DOP2006000195A (lt)
EA (2)	EA018453B1 (lt)
ES (3)	ES2421146T3 (lt)
GE (1)	GEP20125398B (lt)
GT (1)	GT200600406A (lt)
HN (1)	HN2006031275A (lt)
HU (2)	HUE038941T2 (lt)
IL (2)	IL189642A (lt)
LT (1)	LT2960253T (lt)
MA (1)	MA29843B1 (lt)
ME (1)	ME00501B (lt)
MY (1)	MY164457A (lt)
NL (1)	NL1032452C2 (lt)
NO (1)	NO20081718L (lt)
NZ (1)	NZ566774A (lt)
PE (1)	PE20080035A1 (lt)
PL (3)	PL1933871T3 (lt)
PT (3)	PT2960253T (lt)
RS (1)	RS54393B1 (lt)
SI (3)	SI2960253T1 (lt)
TN (1)	TNSN08080A1 (lt)
TW (5)	TWI389919B (lt)
UA (1)	UA94060C2 (lt)
UY (1)	UY29783A1 (lt)
WO (1)	WO2007040912A2 (lt)
ZA (1)	ZA200802971B (lt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
WO2006091930A2 (en) *	2005-02-24	2006-08-31	Massachusetts Eye & Ear Infirmary	Methods and compounds for promoting vessel regression
MY164457A (en) *	2005-09-07	2017-12-15	Amgen Fremont Inc	Human monoclonal antibodies to activin receptor-like kinase-1
JP5537035B2 (ja) *	2006-02-10	2014-07-02	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	Ｃｄｋ阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
AU2012265564B2 (en) *	2006-09-08	2016-05-26	Amgen Inc	Anti-activin A antibodies and uses thereof
US10059756B2 (en)	2006-11-02	2018-08-28	Acceleron Pharma Inc.	Compositions comprising ALK1-ECD protein
AU2016247166B2 (en) *	2006-11-02	2018-09-27	Acceleron Pharma Inc.	ALK1 receptor and ligand antagonists and uses thereof
KR20170012582A (ko) *	2006-11-02	2017-02-02	악셀레론 파마 인코포레이티드	Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
US8642031B2 (en)	2006-11-02	2014-02-04	Acceleron Pharma, Inc.	Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
TWI573802B (zh)	2007-03-06	2017-03-11	安美基公司	變異之活動素受體多肽及其用途
AU2008236765A1 (en) *	2007-04-02	2008-10-16	Amgen Fremont Inc.	Anti-IgE antibodies
ITTV20070126A1 (it)	2007-07-16	2009-01-17	Luca Toncelli	Procedimento ed apparecchiatura per la fabbricazione di lastre ad effet-to venato
MX344733B (es) *	2007-11-09	2017-01-04	Genentech Inc *	Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina.
AU2008323206B2 (en) *	2007-11-12	2014-08-14	U3 Pharma Gmbh	AXL antibodies
JP5596559B2 (ja) *	2008-01-28	2014-09-24	メディミューンリミテッド	安定化アンジオポエチン２抗体とその用途
US7855564B2 (en) *	2008-02-14	2010-12-21	Delaware Capital Formation, Inc.	Acoustic wave device physical parameter sensor
US20110110944A1 (en) *	2008-04-25	2011-05-12	Morphosys Ag	Anti-alk1 antibodies and uses thereof
TWI672151B (zh) *	2008-05-02	2019-09-21	艾西利羅製藥公司	調節血管新生與周圍細胞組成的方法與組合物
EP2291401A2 (en) *	2008-05-15	2011-03-09	Acceleron Pharma, Inc.	Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
US8821870B2 (en) *	2008-07-18	2014-09-02	Allergan, Inc.	Method for treating atrophic age related macular degeneration
LT2370463T (lt)	2008-11-26	2016-12-12	Amgen Inc.	Stabilizuotas aktivino iib receptoriaus variantas
WO2010126169A1 (ja) *	2009-04-30	2010-11-04	協和発酵キリン株式会社	Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物
GB0915515D0 (en) *	2009-09-04	2009-10-07	Ucl Business Plc	Treatment of vasculoproliferative conditions
CA2783715A1 (en) *	2009-12-29	2011-07-07	F. Hoffmann-La Roche Ag	Novel antibody formulation
KR20130087517A (ko)	2010-06-25	2013-08-06	백시바디 에이에스	동종이합체 단백질 구조물
EP2793925B1 (en)	2011-12-19	2019-03-20	Amgen Inc.	Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
EP3447071A1 (en)	2012-01-09	2019-02-27	Pfizer Healthcare Ireland	Mutant antibodies and conjugation thereof
WO2013155447A1 (en)	2012-04-13	2013-10-17	Children's Medical Center Corporation	Tiki inhibitors
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
EP3985024A1 (en) *	2013-02-01	2022-04-20	Atara Biotherapeutics, Inc.	Anti-activin-a compounds for the treatment of ovarian cancer
US9708375B2 (en)	2013-03-15	2017-07-18	Amgen Inc.	Inhibitory polypeptides specific to WNT inhibitors
EP2787006B1 (en) *	2013-04-02	2018-02-28	Miltenyi Biotec GmbH	Anti-CD8 antibody which binding is Ca2+ dependent
EP3041863A4 (en)	2013-09-05	2017-08-16	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA2949237C (en)	2014-05-16	2022-08-23	Amgen Inc.	Assay for detecting th1 and th2 cell populations
WO2016054023A1 (en) *	2014-09-29	2016-04-07	Duke University	Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
GB201503438D0 (en)	2015-02-27	2015-04-15	Ucl Business Plc	Antibodies
AU2016273028B2 (en)	2015-06-05	2019-02-14	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor
KR101983013B1 (ko) *	2015-09-25	2019-05-28	동우 화인켐 주식회사	필름 터치 센서 및 그 제조 방법
JP2017077830A (ja) *	2015-10-21	2017-04-27	Ｋｙｂ株式会社	電動パワーステアリング装置
AU2017205270B2 (en)	2016-01-08	2024-01-18	Nykode Therapeutics ASA	Therapeutic anticancer neoepitope vaccine
EP3413912A4 (en)	2016-02-11	2019-09-25	The Johns Hopkins University	COMPOSITIONS AND METHODS FOR TARGETING ACTIVIN SIGNALING FOR THE TREATMENT OF CANCER
RU2615908C1 (ru) *	2016-05-16	2017-04-11	Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации	Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс
KR20190077306A (ko) *	2016-08-05	2019-07-03	메디뮨 엘엘씨	항-o2 항체 및 이의 용도
CN109843917B (zh)	2016-10-19	2023-10-03	免疫医疗有限责任公司	抗o1抗体及其用途
CA3056011A1 (en)	2017-03-14	2018-09-20	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
CN111954719B (zh)	2018-03-26	2025-07-18	美国安进公司	细胞培养物中产生的抗体的总去岩藻糖基化糖型
BR112022005583A2 (pt)	2019-09-26	2022-09-20	Amgen Inc	Métodos para a produção de composições de anticorpos
EP4162257A1 (en)	2020-06-04	2023-04-12	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
CN111925442B (zh) *	2020-08-19	2022-10-11	重庆医科大学	新冠病毒rbd特异性单克隆抗体和应用
KR20230087539A (ko)	2020-10-15	2023-06-16	암젠 인크	항체 생산 방법에서의 상대적인 비결합 글리칸
TW202317614A (zh)	2021-06-07	2023-05-01	美商安進公司	使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
EP4363456A4 (en) *	2021-06-28	2025-08-13	Trellis Bioscience Inc	ANTI-ALK ANTIBODIES AND THEIR USES
CN115746142A (zh) *	2021-09-03	2023-03-07	开拓药业(广东)有限公司	抗alk-1/抗vegf双特异性抗体及其应用
WO2023059607A1 (en)	2021-10-05	2023-04-13	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
CN121079328A (zh) *	2023-01-18	2025-12-05	开拓药业(广东)有限公司	抗alk-1抗体及其用途
US20250002588A1 (en)	2023-04-07	2025-01-02	Diagonal Therapeutics Inc.	Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024220916A1 (en)	2023-04-20	2024-10-24	Amgen Inc.	Methods of determining relative unpaired glycan content
WO2025038600A1 (en)	2023-08-14	2025-02-20	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) *	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) *	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US5168062A (en) *	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de)	1985-04-01	1990-02-15	Celltech Ltd	Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en) *	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) *	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
US5750172A (en) *	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH0341802A (ja)	1989-07-07	1991-02-22	Ngk Spark Plug Co Ltd	温度補償型マイクロ波ストリップラインフィルタ
US5959177A (en)	1989-10-27	1999-09-28	The Scripps Research Institute	Transgenic plants expressing assembled secretory antibodies
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
EP1690935A3 (en)	1990-01-12	2008-07-30	Abgenix, Inc.	Generation of xenogeneic antibodies
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ES2139598T3 (es)	1990-07-10	2000-02-16	Medical Res Council	Procedimientos para la produccion de miembros de parejas de union especifica.
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) *	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
AU664976B2 (en)	1990-08-29	1995-12-14	Gene Pharming Europe Bv	Homologous recombination in mammalian cells
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1992009690A2 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de)	1991-03-01	2009-08-15	Dyax Corp	Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
EP1471142B1 (en)	1991-04-10	2008-11-19	The Scripps Research Institute	Heterodimeric receptor libraries using phagemids
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
AU2515992A (en) *	1991-08-20	1993-03-16	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5770592A (en)	1991-11-22	1998-06-23	Alcon Laboratories, Inc.	Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en)	1991-11-22	1997-10-21	Alcon Laboratories, Inc.	Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
EP1997894B1 (en) *	1992-02-06	2011-03-30	Novartis Vaccines and Diagnostics, Inc.	Biosynthetic binding protein for cancer marker
SG48760A1 (en)	1992-07-24	2003-03-18	Abgenix Inc	Generation of xenogenetic antibodies
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
KR950704485A (ko) *	1992-11-17	1995-11-20	로이드 제이. 오울드·에드워드 에이, 맥더모 2세	액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
US7592428B1 (en) *	1992-11-17	2009-09-22	Ludwig Institute For Cancer Research	Antibodies which bind specifically to activin receptor like kinases
US6692925B1 (en) *	1992-11-17	2004-02-17	Ludwig Institute For Cancer Research	Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
ATE193301T1 (de) *	1993-03-09	2000-06-15	Genzyme Corp	Verfahren zur isolierung von proteinen aus milch
US6291206B1 (en)	1993-09-17	2001-09-18	Genetics Institute, Inc.	BMP receptor proteins
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5608082A (en) *	1994-07-28	1997-03-04	Agouron Pharmaceuticals, Inc.	Compounds useful as antiproliferative agents and GARFT inhibitors
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) *	1994-12-30	2000-04-04	Hiatt; Andrew C.	Method for producing immunoglobulins containing protection proteins in plants and their use
US5633272A (en)	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en)	1995-04-21	1999-05-27	Cell Genesys, Inc.	Generation of large genomic DNA deletions
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
CA2229557A1 (en) *	1995-08-14	1997-02-27	Creative Biomolecules, Inc.	Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
GB9520822D0 (en)	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US5663272A (en) *	1995-12-22	1997-09-02	Bayer Corporation	Allophanate-modified diphenylmethane diisocyanates and processes for their production and use
AU719327B2 (en)	1996-03-05	2000-05-04	Astrazeneca Ab	4-anilinoquinazoline derivatives
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US5994619A (en)	1996-04-01	1999-11-30	University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus	Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6180651B1 (en) *	1996-04-04	2001-01-30	Bristol-Myers Squibb	Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
SK285353B6 (sk)	1996-04-12	2006-11-03	G. D. Searle & Co.	Substituované benzénsulfónamidy ako proliečivá COX-2 inhibítorov, farmaceutická kompozícia a spôsobich prípravy a použitia
DE19616523A1 (de) *	1996-04-25	1997-11-06	Basf Ag	Polymerisationskatalysatoren mit beta-Diketiminat-Liganden
CA2259222A1 (en) *	1996-06-27	1997-12-31	Pfizer Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
AR007857A1 (es)	1996-07-13	1999-11-24	Glaxo Group Ltd	Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID19430A (id)	1996-07-13	1998-07-09	Glaxo Group Ltd	Senyawa senyawa heterosiklik
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
CZ292843B6 (cs)	1996-07-18	2003-12-17	Merck Frosst Canada & Co.	Derivát pyridinu a farmaceutický prostředek s jeho obsahem
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
ES2301183T3 (es)	1996-12-03	2008-06-16	Amgen Fremont Inc.	Anticuerpo completamente humano que se une al receptor del egfr.
US6034256A (en)	1997-04-21	2000-03-07	G.D. Searle & Co.	Substituted benzopyran derivatives for the treatment of inflammation
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
WO1998050356A1 (en)	1997-05-07	1998-11-12	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
GB2339430A (en)	1997-05-21	2000-01-26	Biovation Ltd	Method for the production of non-immunogenic proteins
EP0984692A4 (en)	1997-05-30	2001-02-21	Merck & Co Inc	ANGIOGENESIS INHIBITORS
DE69838172T2 (de)	1997-08-22	2008-04-10	Astrazeneca Ab	Oxindolylchinazolinderivate als angiogenesehemmer
CO4960662A1 (es)	1997-08-28	2000-09-25	Novartis Ag	Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
EP1017682A4 (en)	1997-09-26	2000-11-08	Merck & Co Inc	NEW ANGIOGENESIS INHIBITORS
BR9814018A (pt)	1997-11-11	2000-09-26	Pfizer Prod Inc	Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
JPH11236333A (ja) *	1997-12-30	1999-08-31	Pfizer Prod Inc	抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
WO1999045031A2 (en)	1998-03-03	1999-09-10	Abgenix, Inc.	Cd147 binding molecules as therapeutics
EP2078752A3 (en) *	1998-03-13	2009-09-23	Ludwig Institute For Cancer Research	ALK-1 responds to TGF-beta and signals through SMAD-1 and SMAD-5
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
IL139934A (en)	1998-05-29	2007-10-31	Sugen Inc	History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
UA60365C2 (uk)	1998-06-04	2003-10-15	Пфайзер Продактс Інк.	Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
AU770555B2 (en)	1998-08-17	2004-02-26	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
JP3495706B2 (ja) *	1998-08-27	2004-02-09	ファイザー・プロダクツ・インク	抗癌薬として有用なアルキニル置換キノリン−２−オン誘導体
EP1107962B1 (en) *	1998-08-27	2005-02-23	Pfizer Products Inc.	Quinolin-2-one derivatives useful as anticancer agents
EP1006113A1 (en) *	1998-12-02	2000-06-07	Pfizer Products Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
DE69934967T2 (de)	1998-12-08	2007-12-06	Biovation Ltd.	Verfahren zur verminderung der immunogenität von proteinen
SG143018A1 (en)	1998-12-23	2008-06-27	Pfizer	Human monoclonal antibodies to ctla-4
EE05627B1 (et)	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
BR0008202A (pt) *	1999-02-11	2002-02-19	Pfizer Prod Inc	Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
US5998206A (en) *	1999-02-23	1999-12-07	Isis Pharmaceuticals Inc.	Antisense inhibiton of human G-alpha-12 expression
US6586447B1 (en) *	1999-04-01	2003-07-01	Pfizer Inc	3,3-disubstituted-oxindole derivatives useful as anticancer agents
TWI262914B (en)	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
KR100478111B1 (ko)	1999-11-05	2005-03-28	가부시키가이샤 아마다	프레스 브레이크 및 프레스 브레이크에 있어서의 유압실린더의 쌍방향 유체 펌프 제어 방법
US6517529B1 (en)	1999-11-24	2003-02-11	Radius International Limited Partnership	Hemodialysis catheter
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
TR200400342T4 (tr) *	1999-11-30	2004-03-22	Pfizer Products Inc.	Farnezil protein transferazı önlemek için kinolin türevleri.
CA2394576A1 (en) *	1999-12-15	2001-06-21	Research Development Foundation	Betaglycan as an inhibin receptor and uses thereof
RS50444B (sr)	2000-02-15	2010-03-02	Sugen Inc.	Inhibitori 2-indolinon protein kinaze supstituisani pirolom
US6584504B1 (en) *	2000-05-26	2003-06-24	Networks Associates Technology, Inc.	Method and apparatus for monitoring internet traffic on an internet web page
JP4044839B2 (ja)	2000-06-22	2008-02-06	ファイザー・プロダクツ・インク	異常細胞増殖を治療するための置換２環式誘導体
CA2420192A1 (en)	2000-09-20	2002-03-28	Human Genome Sciences, Inc.	21 human secreted proteins
MA26040A1 (fr)	2001-01-05	2004-04-01	Pfizer	Des anticorps pour recepteur i de facteur de croissance insulinique
AR042586A1 (es)	2001-02-15	2005-06-29	Sugen Inc	3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP2009027B1 (en) *	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Anti-CD40 monoclonal antibody
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
WO2003048328A2 (en) *	2001-12-03	2003-06-12	Abgenix, Inc.	Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
JP2005512044A (ja)	2001-12-03	2005-04-28	アブジェニックス・インコーポレーテッド	結合特性に基づく抗体分類
JP2005516965A (ja) *	2001-12-28	2005-06-09	アブジェニックス・インコーポレーテッド	抗ｍｕｃ１８抗体を使用する方法
PA8580301A1 (es)	2002-08-28	2005-05-24	Pfizer Prod Inc	Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
CA2508375C (en) *	2002-12-02	2014-05-27	Abgenix, Inc.	Antibodies directed to tumor necrosis factor and uses thereof
HN2004000285A (es) *	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
CN101501213B (zh)	2005-02-04	2013-07-17	Cp凯尔科美国公司	多糖粘液形成菌的靶基因缺失
MY164457A (en) *	2005-09-07	2017-12-15	Amgen Fremont Inc	Human monoclonal antibodies to activin receptor-like kinase-1
JP6943759B2 (ja)	2017-12-28	2021-10-06	株式会社東海理化電機製作所	シフト装置

2006
- 2006-09-06 MY MYPI20080556A patent/MY164457A/en unknown
- 2006-09-06 GT GT200600406A patent/GT200600406A/es unknown
- 2006-09-06 ZA ZA200802971A patent/ZA200802971B/xx unknown
- 2006-09-06 RS RS20080103A patent/RS54393B1/sr unknown
- 2006-09-06 NZ NZ566774A patent/NZ566774A/en unknown
- 2006-09-06 HU HUE15169743A patent/HUE038941T2/hu unknown
- 2006-09-06 HN HN2006031275A patent/HN2006031275A/es unknown
- 2006-09-06 BR BRPI0615766-1A patent/BRPI0615766A2/pt not_active IP Right Cessation
- 2006-09-06 AU AU2006297571A patent/AU2006297571B2/en not_active Ceased
- 2006-09-06 GE GEAP200610627A patent/GEP20125398B/en unknown
- 2006-09-06 EP EP06824915.0A patent/EP1933871B1/en active Active
- 2006-09-06 LT LTEP15169743.0T patent/LT2960253T/lt unknown
- 2006-09-06 DK DK12152953.1T patent/DK2447283T3/en active
- 2006-09-06 SI SI200632285T patent/SI2960253T1/sl unknown
- 2006-09-06 CN CN200680041490.3A patent/CN101517068B/zh active Active
- 2006-09-06 DK DK15169743.0T patent/DK2960253T3/en active
- 2006-09-06 PT PT151697430T patent/PT2960253T/pt unknown
- 2006-09-06 ME MEP-2008-812A patent/ME00501B/me unknown
- 2006-09-06 UA UAA200804286A patent/UA94060C2/ru unknown
- 2006-09-06 PE PE2006001075A patent/PE20080035A1/es not_active Application Discontinuation
- 2006-09-06 PL PL06824915T patent/PL1933871T3/pl unknown
- 2006-09-06 ES ES06824915T patent/ES2421146T3/es active Active
- 2006-09-06 EA EA200800759A patent/EA018453B1/ru not_active IP Right Cessation
- 2006-09-06 DO DO2006000195A patent/DOP2006000195A/es unknown
- 2006-09-06 PL PL12152953T patent/PL2447283T3/pl unknown
- 2006-09-06 AP AP2008004388A patent/AP2723A/xx active
- 2006-09-06 KR KR1020137033726A patent/KR101536506B1/ko not_active Expired - Fee Related
- 2006-09-06 TW TW099108743A patent/TWI389919B/zh not_active IP Right Cessation
- 2006-09-06 CA CA2621371A patent/CA2621371C/en active Active
- 2006-09-06 TW TW103116433A patent/TWI541253B/zh not_active IP Right Cessation
- 2006-09-06 NL NL1032452A patent/NL1032452C2/nl not_active IP Right Cessation
- 2006-09-06 PT PT68249150T patent/PT1933871E/pt unknown
- 2006-09-06 EP EP18170945.2A patent/EP3381945B1/en active Active
- 2006-09-06 AR ARP060103884A patent/AR055152A1/es not_active Application Discontinuation
- 2006-09-06 CN CN201611215981.7A patent/CN107056943B/zh active Active
- 2006-09-06 AP AP2013006963A patent/AP2013006963A0/xx unknown
- 2006-09-06 JP JP2008530231A patent/JP5161777B2/ja not_active Expired - Fee Related
- 2006-09-06 ES ES15169743.0T patent/ES2681656T3/es active Active
- 2006-09-06 KR KR1020087006587A patent/KR101390127B1/ko not_active Expired - Fee Related
- 2006-09-06 SI SI200631985T patent/SI2447283T1/sl unknown
- 2006-09-06 WO PCT/US2006/035096 patent/WO2007040912A2/en not_active Ceased
- 2006-09-06 EP EP12152953.1A patent/EP2447283B1/en active Active
- 2006-09-06 TW TW095132933A patent/TWI370137B/zh not_active IP Right Cessation
- 2006-09-06 DK DK06824915.0T patent/DK1933871T3/da active
- 2006-09-06 TW TW103138817A patent/TWI569807B/zh not_active IP Right Cessation
- 2006-09-06 SI SI200631626T patent/SI1933871T1/sl unknown
- 2006-09-06 UY UY29783A patent/UY29783A1/es not_active Application Discontinuation
- 2006-09-06 KR KR1020137007712A patent/KR101536487B1/ko not_active Expired - Fee Related
- 2006-09-06 TW TW101141374A patent/TWI453218B/zh not_active IP Right Cessation
- 2006-09-06 US US11/517,530 patent/US7537762B2/en active Active
- 2006-09-06 ES ES12152953.1T patent/ES2546069T3/es active Active
- 2006-09-06 PL PL15169743T patent/PL2960253T3/pl unknown
- 2006-09-06 PT PT121529531T patent/PT2447283E/pt unknown
- 2006-09-06 EP EP15169743.0A patent/EP2960253B1/en active Active
- 2006-09-06 EA EA201300320A patent/EA201300320A1/ru unknown
- 2006-09-06 HU HUE12152953A patent/HUE025608T2/en unknown
2008
- 2008-02-21 TN TNP2008000080A patent/TNSN08080A1/en unknown
- 2008-02-21 IL IL189642A patent/IL189642A/en not_active IP Right Cessation
- 2008-03-14 CR CR9819A patent/CR9819A/es unknown
- 2008-04-01 MA MA30800A patent/MA29843B1/fr unknown
- 2008-04-07 NO NO20081718A patent/NO20081718L/no not_active Application Discontinuation
2009
- 2009-03-12 US US12/402,854 patent/US8080646B2/en active Active
2010
- 2010-02-04 CL CL2010000096A patent/CL2010000096A1/es unknown
2011
- 2011-10-26 US US13/282,065 patent/US9221915B2/en active Active
2012
- 2012-03-01 IL IL218429A patent/IL218429A0/en unknown
- 2012-07-02 JP JP2012148146A patent/JP5833978B2/ja not_active Expired - Fee Related
2013
- 2013-07-19 CR CR20130351A patent/CR20130351A/es unknown
2014
- 2014-05-22 CR CR20140239A patent/CR20140239A/es unknown
- 2014-08-13 JP JP2014164638A patent/JP5947840B2/ja not_active Expired - Fee Related
2016
- 2016-12-20 AR ARP160103944A patent/AR107003A2/es unknown
2018
- 2018-08-09 CY CY181100829T patent/CY1120794T1/el unknown

Also Published As

Publication number	Publication date
SI2960253T1 (sl)	2018-10-30
JP5161777B2 (ja)	2013-03-13
EP2960253B1 (en)	2018-06-06
PL1933871T3 (pl)	2013-09-30
EP1933871B1 (en)	2013-04-24
HN2006031275A (es)	2010-10-29
TW201431883A (zh)	2014-08-16
CA2621371A1 (en)	2007-04-12
CN107056943A (zh)	2017-08-18
NZ566774A (en)	2011-11-25
RS20080103A (en)	2009-07-15
BRPI0615766A2 (pt)	2009-06-16
TW201030017A (en)	2010-08-16
JP5833978B2 (ja)	2015-12-16
CN101517068A (zh)	2009-08-26
UY29783A1 (es)	2007-04-30
SI2447283T1 (sl)	2015-12-31
CR20140239A (es)	2014-06-13
JP2009506791A (ja)	2009-02-19
EP2447283B1 (en)	2015-07-15
AP2723A (en)	2013-08-31
US7537762B2 (en)	2009-05-26
JP5947840B2 (ja)	2016-07-06
DK2960253T3 (en)	2018-08-13
AP2008004388A0 (en)	2008-04-30
DK2447283T3 (en)	2015-08-31
CR9819A (es)	2008-12-03
IL189642A0 (en)	2008-06-05
MA29843B1 (fr)	2008-10-03
EP1933871A4 (en)	2009-10-28
PT2447283E (pt)	2015-10-08
HUE038941T2 (hu)	2018-12-28
ME00501B (me)	2011-10-10
KR101390127B1 (ko)	2014-05-13
TWI370137B (en)	2012-08-11
WO2007040912A3 (en)	2009-04-30
CL2010000096A1 (es)	2010-06-25
CN107056943B (zh)	2021-06-08
AR107003A2 (es)	2018-03-07
UA94060C2 (ru)	2011-04-11
TWI389919B (zh)	2013-03-21
EP3381945B1 (en)	2020-08-19
GEP20125398B (en)	2012-02-27
PL2960253T3 (pl)	2018-11-30
KR101536487B1 (ko)	2015-07-13
CN101517068B (zh)	2017-02-08
EP2447283A2 (en)	2012-05-02
GT200600406A (es)	2007-07-13
ES2681656T3 (es)	2018-09-14
HUE025608T2 (en)	2016-03-29
CY1120794T1 (el)	2019-12-11
TNSN08080A1 (en)	2009-07-14
CR20130351A (es)	2013-08-13
EP3381945A1 (en)	2018-10-03
ES2421146T3 (es)	2013-08-29
SI1933871T1 (sl)	2013-10-30
IL218429A0 (en)	2012-04-30
ZA200802971B (en)	2009-10-28
TW201511773A (zh)	2015-04-01
KR20140004261A (ko)	2014-01-10
WO2007040912A2 (en)	2007-04-12
US8080646B2 (en)	2011-12-20
RS54393B1 (sr)	2016-04-28
PL2447283T3 (pl)	2015-12-31
KR101536506B1 (ko)	2015-07-14
DK1933871T3 (da)	2013-07-08
EP1933871A2 (en)	2008-06-25
NL1032452C2 (nl)	2008-01-18
EA201300320A1 (ru)	2014-02-28
EP2447283A3 (en)	2012-06-20
HK1169999A1 (en)	2013-02-15
AU2006297571A2 (en)	2008-05-01
IL189642A (en)	2013-06-27
NL1032452A1 (nl)	2007-03-08
PE20080035A1 (es)	2008-01-30
JP2012228251A (ja)	2012-11-22
US20100197005A1 (en)	2010-08-05
EA018453B1 (ru)	2013-08-30
TWI541253B (zh)	2016-07-11
AU2006297571A1 (en)	2007-04-12
US20070065444A1 (en)	2007-03-22
KR20080045715A (ko)	2008-05-23
MY164457A (en)	2017-12-15
TWI569807B (zh)	2017-02-11
HK1219488A1 (en)	2017-04-07
TWI453218B (zh)	2014-09-21
KR20130042648A (ko)	2013-04-26
PT1933871E (pt)	2013-07-17
CA2621371C (en)	2018-05-15
TW201311728A (zh)	2013-03-16
PT2960253T (pt)	2018-07-31
EA200800759A1 (ru)	2008-08-29
US20120052074A1 (en)	2012-03-01
EP2960253A1 (en)	2015-12-30
NO20081718L (no)	2008-06-03
AU2006297571B2 (en)	2012-03-15
DOP2006000195A (es)	2017-08-15
ES2546069T3 (es)	2015-09-18
AP2013006963A0 (en)	2013-07-31
US9221915B2 (en)	2015-12-29
TW200801043A (en)	2008-01-01
AR055152A1 (es)	2007-08-08
JP2014218514A (ja)	2014-11-20

Publication	Publication Date	Title
TWI370137B (en)	2012-08-11	Human monoclonal antibodies to activin receptor-like kinase-1
HRP20181616T1 (hr)	2018-12-14	Potpuno ljudska anti-vap-1 monoklonska antitijela
IL191340A (en)	2015-08-31	Monoclonal antibodies against e8o
IL189788A0 (en)	2008-08-07	Human monoclonal antibodies to cd70
IL216381A0 (en)	2011-12-29	Antagonistic human light-specific human monoclonal antibodies
IL179672A0 (en)	2007-05-15	Anti-cd3 antibodies
ZA200802051B (en)	2008-12-31	Anti-CD3 antibody formulations
IL231169A0 (en)	2014-03-31	Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
IL177602A0 (en)	2006-12-10	Uses of anti-ctla-4 antibodies
ZA200802641B (en)	2009-02-25	Human monoclonal antibodies to CD70
ZA200901165B (en)	2010-06-30	Antagonistic human light-specific human monoclonal antibodies
ZA200804254B (en)	2009-01-28	Human monoclonal antibodies to O8E
HK1122825A (en)	2009-05-29	Human monoclonal antibodies to o8e